Company
genedrive PLC
LON:GDR
genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms.
240 stories · page 2 of 12
Genedrive slumps on higher full year losses
Revenue in the 12 months to 30 June fell to £50,000 from £690,000 a year prior
Genedrive shares soar 25% on US FDA talks
The company is seeking regulatory approval in the US for its Genedrive MT-RNR1 ID kit
Genedrive gets UK coronavirus test device approval
The company’s kit is a rapid molecular diagnostic test that delivers positive results as quickly as seven-and-a-half minutes and negative results within 17 minutes
genedrive readies system for antibiotic-induced hearing loss launch
The group is seeking CE mark clearance for the new Genedrive system in the coming weeks and prior to the commercial launch of the assay, investors were told
Genedrive overcomes technical hurdles with COVID-19 diagnostic kit
The company has overcome significant obstacles in the development of the kit, which it believes will be superior to competing products
genedrive soars as it confirms receipt of Indian import licence for COVID-19 test
The licence follows approval of the test by the Indian Centre for Medical Research on April 30
genedrive COVID-19 PCR test approved by the Indian regulator
The plan is to begin “commercial activities” through its existing local distributor Divoc Health, the company said
Genedrive says HCV test passes independent real-world study with flying colours
The study yielded sensitivity specifications of 96.2-100% and specificity specifications of 98.7-99.5%
Genedrive’s inclusion in a Public Health England framework pact positive for future revenues, says broker
The framework allows Public Health England to issue call-off orders for products and services up to a combined £3bn
Genedrive included in a Public Health England framework agreement for diagnostic equipment and services
All of the company’s three CE-marked products fall within the framework agreement, investors were told
genedrive included in a Public Health England framework agreement for diagnostic equipment and services
All of the company’s three CE-marked products fall within the framework agreement, investors were told
Genedrive optimistic about second half of financial year as it eyes revenue potential from existing contracts
The diagnostics firm is confident in the contract with Beckman Coulter Life Sciences and the ongoing opportunity with a European Ministry of Health